Callas D D, Clark T L, Moreira P L, Lansden C, Gawryl M S, Kahn S, Bermes E W
Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA.
Clin Chem. 1997 Sep;43(9):1744-8.
Red blood cell (RBC) replacement solutions are being developed as alternatives to allogeneic RBC use in blood transfusions in the treatment of massive trauma, to achieve hemodynamic stability during elective surgery, and to increase oxygen-carrying capacity in anemia. Hemoglobin-based oxygen carrier (HBOC)-201 (Biopure Corp.) is a purified, sterile, isosmotic glutaraldehyde-polymerized bovine hemoglobin. Because this product is acellular, blood components containing this substance appear hemolyzed. This study reports on the interferences produced by the presence of HBOC-201 in a variety of clinical assays. This product was added in vitro at concentrations up to 60 g/L (6.0 g/dL) to normal human serum, plasma, or whole blood before testing for serum chemistries, coagulation profiles, and hematology and blood bank assays. In addition, a set of normal human sera containing HBOC-201 was supplemented with various therapeutic drugs and assayed for these agents. The results of these studies demonstrate that the presence of HBOC-201 in blood components does not result in significant analytical interference that would be of concern with many clinical assays at HBOC-201 concentrations encountered during routine clinical use of this RBC replacement solution in patients.
红细胞（RBC）替代溶液正在被开发，作为异体红细胞在大量创伤治疗输血中的替代品，用于在择期手术期间实现血流动力学稳定，并提高贫血患者的携氧能力。基于血红蛋白的氧载体（HBOC）-201（百特纯公司）是一种纯化、无菌、等渗的戊二醛聚合牛血红蛋白。由于该产品无细胞，含有这种物质的血液成分会出现溶血现象。本研究报告了HBOC-201在各种临床检测中产生的干扰。在进行血清化学、凝血指标、血液学和血库检测之前，将该产品以高达60 g/L（6.0 g/dL）的浓度体外添加到正常人血清、血浆或全血中。此外，向一组含有HBOC-201的正常人血清中添加各种治疗药物，并对这些药物进行检测。这些研究结果表明，在该红细胞替代溶液用于患者的常规临床使用过程中，血液成分中HBOC-201的存在不会导致许多临床检测所关注的显著分析干扰。
